LungCancer News & Analysis
3 articles
Market Mood
Cullinan (CFG) Files for FDA Approval of Zipalertinib Lung Drug
Cullinan Oncology (CFG) has initiated a filing with the U.S. Food and Drug Administration (FDA) for its drug zipalertinib, which targets lung cancer. This step represents a significant moment in the drug development process, as FDA approval is a key milestone for pharmaceutical companies. The timeline for when the FDA might evaluate this application has not been disclosed. For investors, FDA filings can influence stock performance, and successful approval could lead to increased market potential for Cullinan's products.
Read More: Cullinan (CFG) Files for FDA Approval of Zipalertinib Lung Drug
AstraZeneca Acquires Zegfrovy for $1.5 Billion Lung Cancer Market
AstraZeneca PLC (NYSE: AZN) is paying $600 million upfront for global rights to Zegfrovy from Dizal Pharmaceutical Co., Ltd, with a potential total value of $1.5 billion if development and sales milestones are met. Zegfrovy, approved in the U.S. and China, targets a specific lung cancer patient group, addressing an unmet need. In the Phase III WU-KONG28 trial, it achieved median progression-free survival of 10.3 months compared to 7.5 months for chemotherapy. This acquisition strengthens AstraZeneca's oncology portfolio and could enhance its market position in lung cancer treatment, offering potential benefits for investors.
Read More: AstraZeneca Acquires Zegfrovy for $1.5 Billion Lung Cancer Market
AbbVie (ABBV) Presents Lung Cancer Data at WCLC 2026 Conference
AbbVie (ABBV) presented lung cancer data at the World Conference on Lung Cancer (WCLC) 2026, including results for ABBV-1480, which achieved a 90.0% objective response rate in squamous NSCLC and 75.9% in non-squamous NSCLC when combined with platinum-based chemotherapy. Safety data for ABBV-706 showed nausea in 35.8% of patients and grade 3+ pneumonitis or interstitial lung disease in 1.7% of patients.
Read More: AbbVie (ABBV) Presents Lung Cancer Data at WCLC 2026 Conference